- Home
- VRAX vs POAI Comparison
VRAX vs POAI Comparison
Compare VRAX & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- POAI
- Stock Information
- Founded
- VRAX 2013
- POAI 2002
- Country
- VRAX United Kingdom
- POAI United States
- Employees
- VRAX N/A
- POAI N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- POAI Industrial Specialties
- Sector
- VRAX Health Care
- POAI Health Care
- Exchange
- VRAX Nasdaq
- POAI Nasdaq
- Market Cap
- VRAX 7.3M
- POAI 9.7M
- IPO Year
- VRAX 2022
- POAI N/A
- Fundamental
- Price
- VRAX $1.94
- POAI $1.57
- Analyst Decision
- VRAX
- POAI Hold
- Analyst Count
- VRAX 0
- POAI 1
- Target Price
- VRAX N/A
- POAI N/A
- AVG Volume (30 Days)
- VRAX 300.5K
- POAI 2.8M
- Earning Date
- VRAX 02-05-2025
- POAI 03-27-2025
- Dividend Yield
- VRAX N/A
- POAI N/A
- EPS Growth
- VRAX N/A
- POAI N/A
- EPS
- VRAX N/A
- POAI N/A
- Revenue
- VRAX $84,872.00
- POAI $1,484,223.00
- Revenue This Year
- VRAX $5,169.18
- POAI N/A
- Revenue Next Year
- VRAX $66.97
- POAI $569.48
- P/E Ratio
- VRAX N/A
- POAI N/A
- Revenue Growth
- VRAX 7.03
- POAI N/A
- 52 Week Low
- VRAX $0.60
- POAI $0.55
- 52 Week High
- VRAX $9.00
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- VRAX 48.34
- POAI 58.55
- Support Level
- VRAX $1.58
- POAI $1.37
- Resistance Level
- VRAX $2.10
- POAI $1.59
- Average True Range (ATR)
- VRAX 0.24
- POAI 0.12
- MACD
- VRAX 0.01
- POAI -0.02
- Stochastic Oscillator
- VRAX 44.59
- POAI 61.23
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.